ABSTRACT

Objective: The goal was to test the efficacy of NCE-2 and NCE-3, substituted synthesized imidazoles N-type calcium channel blockers, in a rat model of streptozotocin (STZ) induced neuropathic pain. Method: NCE-2 and NCE-3 were evaluated for streptozotocin (STZ)- induced diabetic neuropathy for treatment of neuropathic pain. Diabetes mellitus has been induced in male Sprague Dawley rats by injecting STZ at a dose of 45 mg/kg intravenously into the tail vein. In diabetic neuropathic rats, NCE-2 and NCE-3 were dosed orally at 10 and 30 mg/kg. Mechanical allodynia and cold allodynia have been analysed using increasing weight von Frey filaments and acetone, with behaviour monitored for one minute. Results: Overall, the findings show that the NCE-2 and the NCE-3 can be a promising option for additional studies on the neuropathic pain mitigation mechanism. With regard to both mechanical and cold allodynia, paw withdrawal threshold (PWT) and MPE % (Mechanical Allodynia), paw withdrawal latency (PWL) and % MPE (Cold Allodynia) were determined. In this Study sub-acute therapy of NCE-2 at dose 10 and 30 mg/kg exhibited 19.5% and 44.7% reversal of neuropathic pain while with treatment of NCE-3 at dose 10 and 30 mg/kg exhibited 25.7% and 61.0% reversal of mechanical allodynia a symptom of neuropathic pain. In Cold allodynia study, NCE-2 at dose 10 and 30 mg/kg exhibited 23.4 and 43.7% reversal of neuropathic pain while with treatment of NCE-3 atdose 10 and 30 mg/kg exhibited 36.4% and 65.3% reversal neuropathic pain. NCE-2 and NCE-3 demonstrated dose dependent efficacy in reversing mechanical and cold allodynia. Keywords: NCE-2, NCE-3, Mechanical Allodynia, Cold allodynia
Publication date: 01/09/2021

https://ijbpas.com/pdf/2021/September/MS_IJBPAS_2021_6236.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.9.6236